Efficacy of Low-Dose Radioiodine Ablation in Low- and Intermediate-Risk Differentiated Thyroid Cancer: A Retrospective Comparative Analysis.
No Thumbnail Available
Identifiers
Date
2020-02-21
Authors
Gómez-Pérez, Ana María
García-Alemán, Jorge
Molina-Vega, María
Sebastián Ochoa, Arantzazu
Pérez García, Pilar
Mancha Doblas, Isabel
Tinahones, Francisco J
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
(1) Background-low-dose radioiodine ablation is an accepted strategy for the treatment of low- and intermediate-risk thyroid carcinomas, although there is no international consensus. The aim of this study is to describe the clinical experience with low-dose radioiodine ablation in patients with low- and intermediate-risk thyroid cancer compared to high-dose ablation. (2) Methods-174 patients with low- and intermediate-risk thyroid cancer, 90 treated with low-dose ablation and 84 treated with high-dose ablation, were included. The primary endpoint was response to treatment one year after ablation, defined by stimulated thyroglobulin, whole body scan and ultrasound imaging. (3) Results-an excellent response rate of 79.8% in the low-dose group and 85.7% in the high-dose group was observed (p = 0.049). Stimulated thyroglobulin at the moment of ablation (p = 0.032) and positive antithyroglobulin antibodies (p
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
antithyroglobulin antibodies, differentiated thyroid cancer, low-dose ablation, low-risk, radioiodine